Supplementary Table 3.
Baseline Characteristics of the Study Population, Stratified by Type of Calcineurin Inhibitor
| Variables | Immunosuppressant |
Total (N = 243) | P value | |
|---|---|---|---|---|
| CsA/other (n = 81) | TAC (n = 162) | |||
| Male sex | 66 (81.48) | 105 (64.81) | 171 (70.37) | .0073 |
| Age at symptoms, y | 68 (60.5–73.5) | 61 (53.0–68.0) | 63 (55.0–69.0) | |
| Location of patient at occurrence of symptoms | .4631 | |||
| Home | 74 (91.36) | 143 (88.27) | 217 (89.30) | |
| Hospital | 7 (8.64) | 19 (11.73) | 26 (10.70) | |
| Place of management | .0831 | |||
| Home | 7 (8.64) | 32 (19.75) | 39 (16.05) | |
| Ward | 61 (75.31) | 106 (65.43) | 167 (68.72) | |
| ICU | 13 (16.05) | 24 (14.81) | 37 (15.23) | |
| Time between last LT and COVID-19 symptoms, y | 12 (6.2–18.9) | 7 (2.0–13.3) | 8 (3.1–15.0) | |
| Missing | 1 (1.23) | 5 (3.09) | 6 (2.47) | |
| Indication for LT | ||||
| Decompensated cirrhosis | 51 (62.96) | 90 (55.56) | 141 (58.02) | .27 |
| Hepatocellular carcinoma | 21 (25.93) | 42 (25.93) | 63 (25.93) | >.9999 |
| Other | 9 (11.11) | 31 (19.14) | 40 (16.46) | .1118 |
| Body mass index, kg/m2 | 26.3 (23.5–29.7) | 25.7 (23.4–29.4) | 25.9 (23.4–29.4) | .6612 |
| Chronic kidney diseasea | 22 (27.16) | 27 (16.67) | 49 (20.16) | .0546 |
| Coronary artery disease | 3 (3.70) | 14 (8.64) | 17 (7.00) | .1548 |
| Comorbidities, n | .0003 | |||
| 0 | 11 (13.58) | 46 (28.40) | 57 (23.46) | |
| 1 | 20 (24.69) | 59 (36.42) | 79 (32.51) | |
| ≥2 | 50 (61.73) | 57 (35.19) | 107 (44.03) | |
| Drugs | ||||
| β-Blockers | 20 (24.69) | 30 (18.52) | 50 (20.58) | .2618 |
| ACE inhibitors or angiotensin II receptor antagonists | 33 (40.74) | 26 (16.05) | 59 (24.28) | <.0001 |
| Type of immunosuppressant | ||||
| CsA | 29 (35.80) | 0 (0.00) | 29 (11.93) | <.0001 |
| TAC | 0 (0.00) | 162 (100.00) | 162 (66.67) | <.0001 |
| MMF | 50 (61.73) | 69 (42.59) | 119 (48.97) | .0049 |
| mTOR inhibitor | 23 (28.40) | 14 (8.64) | 37 (15.23) | <.0001 |
| Steroids | 14 (17.28) | 42 (25.93) | 56 (23.05) | .1316 |
| Other | 0 (0.00) | 1 (0.62) | 1 (0.41) | >.9999 |
| Outcome | .0033 | |||
| Alive | 56 (69.14) | 138 (85.19) | 194 (79.84) | |
| Dead | 25 (30.86) | 24 (14.81) | 49 (20.16) | |
| Time between symptoms and last follow-up, d | 60 (23–83) | 66 (39–87) | 65 (35–87) | .127 |
| Missing | 1 (1.23) | 5 (3.09) | 6 (2.47) | |
| Cause of death | ||||
| Refractory pneumonia | 21 (84.00) | 17 (70.83) | 38 (77.55) | .2695 |
| Liver-related death | ||||
| Without lung failure | 0 (0.00) | 1 (4.17) | 1 (2.04) | .4898 |
| With lung failure | 2 (8.00) | 1 (4.17) | 3 (6.12) | >.9999 |
| Other | 2 (8.00) | 5 (20.83) | 7 (14.29) | .2467 |
NOTE. Data are presented n (%) or median (1st–3rd quartile).
mTOR, mammalian target of rapamycin.
a
Plasma creatinine >2 mg/dL.